Using MRI to assess growth patterns in liver metastases from colorectal cancer
Noninvasive Evaluation in Diagnosis and Treatment of Histopathological Growth Patterns in Colorectal Liver Metastases Using MR Elastography-based Shear Strain Mapping
Shengjing Hospital · NCT06208397
This study is testing if a special type of MRI can help doctors see how colorectal cancer spreads in the liver to improve treatment plans for patients.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 50 (estimated) |
| Ages | 18 Years to 80 Years |
| Sex | All |
| Sponsor | Shengjing Hospital (other) |
| Locations | 1 site (Shenyang, Liaoning) |
| Trial ID | NCT06208397 on ClinicalTrials.gov |
What this trial studies
This observational study aims to evaluate the effectiveness of Magnetic Resonance Elastography (MRE) in noninvasively detecting histopathological growth patterns (HGP) in patients with colorectal liver metastases (CRLM). By measuring tumor-liver adhesion, the study seeks to correlate imaging findings with pathophysiological changes in the liver. Given the high incidence and mortality rates associated with colorectal cancer, understanding HGP could significantly influence preoperative treatment planning and improve patient outcomes. The study will include patients with confirmed CRLM who meet specific eligibility criteria.
Who should consider this trial
Good fit: Ideal candidates for this study are patients diagnosed with colorectal liver metastases who have undergone surgical pathology evaluation.
Not a fit: Patients with CRLM smaller than 1 cm or those with significant organ dysfunction or other malignancies may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could enhance preoperative treatment planning for patients with colorectal liver metastases, potentially improving survival rates.
How similar studies have performed: While there have been efforts to identify histopathological growth patterns through imaging, this specific approach using MRE is relatively novel and has not been extensively tested in prior studies.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Diagnosed CRLM * Pathologic results obtained in surgical patients * No contraindications for magnetic resonance imaging examination Exclusion Criteria: * Image quality does not meet the measurement requirements. * the diameter of CRLM \<1cm * Combined with other important organ dysfunction * Combined with malignant tumor * Patients who do not sign an informed consent * Patients with metallic implants or foreign bodies in their bodies (pacemakers, artificial metallic heart valves, metal joints, metal implants, and those who cannot remove dentures, insulin pumps, or contraceptive rings)
Where this trial is running
Shenyang, Liaoning
- Shengjing Hospital of China Medical University — Shenyang, Liaoning, China (RECRUITING)
Study contacts
- Principal investigator: Yu Shi, M.D. — Shengjing Hospital
- Study coordinator: Yu Shi, M.D.
- Email: 18940259980@163.com
- Phone: 18940259980
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
Conditions: Metastatic Colorectal Cancer, colorectal cancer liver metastasis, Magnetic Resonance Imaging, Magnetic Resonance Elastography, Histopathological growth patterns